Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Spermatogenesis Abnormali… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Spermatogenesis Abnormalities following Hormonal Therapy in Transwomen

Artikel i vetenskaplig tidskrift
Författare S. Jindarak
K. Nilprapha
T. Atikankul
A. Angspatt
P. Pungrasmi
S. Iamphongsai
P. Promniyom
P. Suwajo
Gennaro Selvaggi
P. Tiewtranon
Publicerad i Biomed Research International
Volym 2018
Sidor 1-5
ISSN 2314-6133
Publiceringsår 2018
Publicerad vid Institutionen för kliniska vetenskaper, Avdelningen för plastikkirurgi
Sidor 1-5
Språk en
Länkar https://doi.org/10.1155/2018/791948...
Ämneskategorier Klinisk medicin

Sammanfattning

Objective. To measure spermatogenesis abnormalities in transwomen at the time of sex reassignment surgery (SRS) and to analyze the association between hormonal therapy duration and infertility severity. Design. Retrospective study. Setting. University hospital. Patients. One-hundred seventy-Three transwomen who underwent SRS from January 2000 to December 2015. Interventions. All orchidectomy specimens were retrospectively reviewed and classified. History of hormonal therapy duration was retrieved from medical records. Main Outcome Measures. Histological examinations of orchidectomy specimens were performed to assess spermatogenesis. Results. One-hundred seventy-Three orchidectomy specimens were evaluated. Histological examinations showed maturation arrest in 36.4, hypospermatogenesis in 26, Sertoli cell-only syndrome in 20.2, normal spermatogenesis in 11, and seminiferous tubule hyalinization in 6.4 of the specimens. Spermatogenesis abnormality severity was not associated with the total therapy duration (P=0.81) or patient age at the time of surgery (P=0.88). Testicular volumes and sizes were associated with spermatogenesis abnormality severity (P=0.001 and P=0.026, right testicle and left testicle, resp.). Conclusion(s). Feminizing hormonal treatment leads to reductions in testicular germ cell levels. All transwomen should be warned about this consequence, and gamete preservation should be offered before starting hormonal treatment.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?